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Renal sympathetic denervation (RDN) has been demonstrated as an antihypertensive treatment in resistant hypertension 
patients, and triggers additional positive effects on glucose metabolism and insulin sensitivity in type 2 diabetes. The clinical 
implications of RDN in patients with type 2 diabetes, diabetic nephropathy and resistant hypertension have not yet been 
fully defined. 
We hypothesized that the small antihypertensive effects of RDN treatment will induce additional benefits on renal function 
in CKD patients with type 2 diabetes and resistant hypertension. 
We report the effects of RDN in two patients with type 2 diabetes, diabetic nephropathy, stage 3 chronic kidney disease 
and resistant hypertension. The blood pressure (BP) reduction after RDN was an 8-9% reduction of ABPM (sustained at 
consecutive follow-up visits at 3 and 6 months when compared to the baseline) and restoration of the night time dipping 
pattern was associated with amelioration of albuminuria (UAR).
As proteinuria may accelerate kidney disease progression to end-stage renal failure, recognition of the antiproteinuric 
treatment is essential for providing renoprotection.  Therefore, randomized clinical trials are required to assess the impact 
of reported changes. 
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Introduction
Diabetes and hypertension are two 
main causes of chronic kidney disea-
se (CKD) and diabetic nephropathy is 
the leading cause of end-stage renal 
disease (ESRD). (1,2) Chronic kidney 
disease is responsible for sympathetic 
nervous system hyperactivation that 
leads to fluid overload, aggravation of 
hypertension and further deterioration 
and loss of renal function. (3) Despite 
the available pharmacological inhibition 
of the sympathetic nervous system, 
pharmacotherapy does not provide 
adequate effects in clinical practice; 
thus, renal sympathetic denervation 
(RDN) which produces multilevel inhibi-
tion of the sympathetic nervous system, 
that triggers additional positive effects 
on glucose metabolism and insulin sen-
sitivity, could be a therapeutic option for 
treating resistant hypertension in CKD 
patients. (4-7)
Case reports
We present male patients (66 and 
57-years-old respectivly) with resistant 
hypertension (RH), diabetes (type 2: 
HbA1c 6.6 and 7.1%) with diabetic 
nephropathy (increased urinary albu-
min excretion (UAE) with no hematuria 
and normal kidney ultrasound dimen-
sions) and chronic kidney disease 
grade III (eGFR-MDRD 30 and 34 ml/
min/1.73m2). Before the RDN inter-
vention, antihypertensive treatment 
was optimized (BHS/NICE treatment 
algorithm), and non-concordance 
with pharmacotherapy and secondary 
forms of hypertension were excluded. 
Blood pressure was resistant to trea-
tment with six antihypertensive drugs 
from different classes (diuretic, angi-
otensin-converting enzyme inhibitor 
or angiotensin receptor blocker, calci-
um channel blocker, direct vasodilator 
(urapidil), centrally acting sympatho-
lytic (moxonidine) and aldosterone 
antagonist (spironolactone)), statin 
therapy and oral hypoglicemic drugs. 
The RDN method, and its risks and 
benefits were explained to the patients 
and written consent was obtained. 
After the RDN procedure, the patients 
were stable and without a worsening of 
renal function. The 24-hour ambulatory 
blood pressure monitoring (ABPM) 
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and laboratory analysis were assessed 
at baseline (before RSD) and at 3 and 6 
month follow-up visits. The ABPM reve-
aled hypertension with non-dipping BP 
pattern before RDN. The blood pre-
ssure (BP) reduction after RDN was an 
8-9% reduction of ABPM (sustained at 
follow-up visits at 3 and 6 months when 
compared to the baseline). The RDN 
restored the dipping BP pattern. An 
additional positive effect was observed 
on proteinuria alleviation: after the pro-
cedure UAE was 7.9 mg/mmol in the 
first patient (before RDN 8.3), and 30 
mg/mmol in the second patient (before 
RDN 400) with a stable value of HbA1c 
(6.5 and 6.9%).
Discussion
Resistant  hypertension is associated 
with a hyperactive sympathetic nervous 
system and directly linked with a high 
risk of target organ damage. (5,6,7) 
Normal circadian BP rhythm includes 
nocturnal BP decline – the dipping BP 
pattern (more than 10% sleep-time rela-
tive BP decline). In patients with type 2 
diabetes, a non-dipping pattern is highly 
correlated with the rate of UAE; 80% of 
patients with albuminuria A3 (UAE >30 
mg/mmol/L) were found to have loss 
of sleep-time BP decline. (8)  The non-
dipping BP pattern is associated with a 
lesser BP response to antihypertensive 
medication, accelerates kidney disease 
progression to end-stage renal failure 
and increases the risk of cardiovascular 
complications. (8) Evidence of RDN 
reducing office BP levels and resto-
ring dipping pattern in a small series 
of 15 patients with mean eGFR 31 mL/
min/1.73m2 were reported; but with no 
significant decrease in proteinuria. (7)  
Conclusion
Due to potentially beneficial multiple risk 
factor reductions, as well as safety con-
cerns, a focused assessment of already 
obtained data from patients with type 
2 diabetes, diabetic nephropathy and 
resistant hypertension after RDN inter-
vention should be of importance.
